Tag - DYN

Stifel initiated coverage of Dyne Therapeutics (NASDAQ:DYN) with a “buy” rating and $29 price target. The stock closed at $18.64 on Oct. 9. “We view Dyne as an emerging leader in the neuromuscular space, and our...